SLDB Stock Overview
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States.
+ 1 more risk
Solid Biosciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.50|
|52 Week High||US$4.92|
|52 Week Low||US$0.42|
|1 Month Change||-38.72%|
|3 Month Change||-43.71%|
|1 Year Change||-86.90%|
|3 Year Change||-90.97%|
|5 Year Change||n/a|
|Change since IPO||-97.80%|
Recent News & Updates
Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results
It's shaping up to be a tough period for Solid Biosciences Inc. ( NASDAQ:SLDB ), which a week ago released some...
Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates
The latest analyst coverage could presage a bad day for Solid Biosciences Inc. ( NASDAQ:SLDB ), with the analysts...
|SLDB||US Biotechs||US Market|
Return vs Industry: SLDB underperformed the US Biotechs industry which returned -21.4% over the past year.
Return vs Market: SLDB underperformed the US Market which returned -12.3% over the past year.
|SLDB Average Weekly Movement||18.3%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: SLDB is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.
Volatility Over Time: SLDB's weekly volatility has increased from 12% to 18% over the past year.
About the Company
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company’s lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients’ muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids.
Solid Biosciences Fundamentals Summary
|SLDB fundamental statistics|
Is SLDB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SLDB income statement (TTM)|
|Cost of Revenue||US$5.74m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.71|
|Net Profit Margin||-660.25%|
How did SLDB perform over the long term?See historical performance and comparison
Is Solid Biosciences undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SLDB's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SLDB's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: SLDB is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Biotechs industry average.
PE vs Market: SLDB is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SLDB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SLDB is good value based on its Price-To-Book Ratio (0.3x) compared to the US Biotechs industry average (1.5x).
How is Solid Biosciences forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SLDB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SLDB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SLDB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SLDB's revenue (55% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: SLDB's revenue (55% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SLDB is forecast to be unprofitable in 3 years.
How has Solid Biosciences performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SLDB is currently unprofitable.
Growing Profit Margin: SLDB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SLDB is unprofitable, and losses have increased over the past 5 years at a rate of 9.8% per year.
Accelerating Growth: Unable to compare SLDB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SLDB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: SLDB has a negative Return on Equity (-43.46%), as it is currently unprofitable.
How is Solid Biosciences's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: SLDB's short term assets ($198.6M) exceed its short term liabilities ($21.7M).
Long Term Liabilities: SLDB's short term assets ($198.6M) exceed its long term liabilities ($301.0K).
Debt to Equity History and Analysis
Debt Level: SLDB is debt free.
Reducing Debt: SLDB has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SLDB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SLDB has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 8.3% each year.
What is Solid Biosciences's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SLDB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SLDB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SLDB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SLDB's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SLDB has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ilan Ganot (47 yo)
Mr. Ilan Ganot is Co- Founder of Solid Biosciences Inc. and has been its Chief Executive Officer and Director since 2013. He serves as the President of Solid Biosciences Inc. since June 26, 2018. He is al...
CEO Compensation Analysis
Compensation vs Market: Ilan's total compensation ($USD3.29M) is above average for companies of similar size in the US market ($USD770.27K).
Compensation vs Earnings: Ilan's compensation has increased whilst the company is unprofitable.
Experienced Management: SLDB's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: SLDB's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.
Solid Biosciences Inc.'s employee growth, exchange listings and data sources
- Name: Solid Biosciences Inc.
- Ticker: SLDB
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$56.146m
- Shares outstanding: 112.81m
- Website: https://www.solidbio.com
Number of Employees
- Solid Biosciences Inc.
- 141 Portland Street
- Fifth Floor
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/24 00:00|
|End of Day Share Price||2022/05/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.